Dosage and administration
adults and children 12 years and older Apply to external vaginal area not more than 3 to 4 times a day children under 12 years consult a doctor
adults and children 12 years and older Apply to external vaginal area not more than 3 to 4 times a day children under 12 years consult a doctor
Vagisil Sensitive Skin Anti-Itch Creme
Drug Facts
Hydrocortisone Acetate 1%
Anti-itch
For temporary external feminine itching.
For external use only
Avoid contact with eyes
condition worsens, or if symptoms persist for more than 7 days, or clear up and occur again within a few days.
you have a vaginal discharge. Consult a physician.
If swallowed, get medical help or contact a Poison Control Center right away.
| adults and children 12 years and older | Apply to external vaginal area not more than 3 to 4 times a day |
| children under 12 years | consult a doctor |
water, cetyl ethylhexanoate, glycerin, PEG-40 hydrogenated castor oil, glyceryl dilaurate, dimethicone, colloidal oatmeal, aloe barbadensis leaf extract, sodium polyacrylate, caprylyl glycol, ceteareth-20, glyceryl oleate, acrylates/C10-30 alkyl acrylate crosspolymer, cyclopentasiloxane, trideceth-6, sodium hydroxide, disodium EDTA, sorbic acid, PEG/PPG-18/18 dimethicone, tocopheryl acetate, maltodextrin, phenoxyethanol.
Vagisil Sensitive Skin Anti-Itch Creme, 1% Hydrocortisone
Net. Wt. 1 oz. (28 g)
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1039349 | hydrocortisone acetate 1 % Vaginal Cream | PSN | 3 |
| 1039353 | Vagisil Satin 1 % Vaginal Cream | PSN | 3 |
| 1039353 | hydrocortisone acetate 10 MG/ML Vaginal Cream [Vagisil Satin] | SBD | 3 |
| 1039349 | hydrocortisone acetate 10 MG/ML Vaginal Cream | SCD | 3 |
| 1039349 | hydrocortisone acetate 1 % Vaginal Cream | SY | 3 |
| 1039353 | Vagisil Satin 1 % Vaginal Cream | SY | 3 |
| 1039353 | Vagisil Satin 10 MG/ML Vaginal Cream | SY | 3 |
| Class | Version | Type | Effective |
|---|---|---|---|
| HYDROCORTISONE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 11509-5101-1 | 2020-04-20 | C162847 | 48780-1 | 9d75b9cf-e585-f424-e053-dadaa90a57ce | Vagisil Anti-Itch Crème Maximum Strength, Sensitive Skin Formula |
| 11509-5101-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9cf-e585-f424-e053-dadaa90a57ce | Vagisil Anti-Itch Crème Maximum Strength, Sensitive Skin Formula |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 11509-5101-1 | Vagisil Anti-Itch Creme Maximum Strength Sensitive Skin Formula | 28 g in 1 CARTON | CREAM | 28 | 3 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 11509-5101 | VAGISIL ANTI-ITCH CREME MAXIMUM STRENGTH SENSITIVE SKIN FORMULA (HYDROCORTISONE ACETATE) CREAM [COMBE INCORPORATED] | 3 | Current NDC, Legacy NDC, 1 package rows | 20200421_9b69fa24-02dd-43e4-a81f-9a37968d7099.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 11509-5101-1 | GM - Gram | 11509-5101 | 4aee3eac-9efd-4774-8599-2423ca228886 | 1 | 2022-06-06 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 11509-5101 | 11509-5101-1 |
Every source-derived ingredient row is available through these pages.
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vagisil Anti-Itch Creme Maximum Strength Sensitive Skin Formula | HYDROCORTISONE ACETATE | Combe Incorporated | 9b69fa24-02dd-43e4-a81f-9a37968d7099 | 2024-12-12 | Warnings | 11509-5101-1 11509-5101 11509510101 9b69fa24-02dd-43e4-a81f-9a37968d7099 |
Adverse event summaries are temporarily unavailable. Other product information remains available.